Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ENSG00000272854, "Novel transcript, antisense to BCAP29," is a long non-coding RNA (lncRNA) that overlaps the BCAP29 gene locus in the antisense direction. It is annotated as part of the lncRNA class, and current databases do not describe a known biological function, disease association, drug interaction, or biomarker role for this transcript. It is not considered a canonical therapeutic target such as a receptor, enzyme, or transporter[5]. Note: If you are looking for information on BCAP29 itself (B-cell receptor associated protein 29), see the entries for that protein-coding gene (Ensembl: ENSG00000075790), which encodes a membrane protein implicated in membrane trafficking and apoptosis, and is of more classical therapeutic interest[1][3][7]. The current entry (ENSG00000272854) is simply an annotated non-coding RNA gene with no established clinical or pharmacological significance[5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Novel transcript, antisense to BCAP29.